Ruilin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruilin Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Yuhui Liao
Institute for Engineering Medicine Kunming Medical University Kunming Yunnan China
3 shared publications Junrui Li
Institute For Engineering Medicine NHC Key Laboratory of Drug Addiction Medicine Kunming Medical University Kunming China
2 shared publicationsQiuxia Gao
Institute for Engineering Medicine Kunming Medical University Kunming Yunnan China
2 shared publicationsAnyun Xu
School of Material and Energy Institute of International Rivers and Eco‐Security School of Chemical Science and Technology Yunnan University Kunming Yunnan 650091 China
1 shared publicationBin Li
School of Inspection Ningxia Medical University Yinchuan Ningxia China
1 shared publication- Chenguang Shen
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Ministry of Education Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Wiley in Exploration
- Vol. 6 (3)
Nano‐Silver‐Selenium Liquid Dressing Facilitates Treatment of Monkeypox and Prevention of Viral Transmission in a Surrogate Mouse Model
The recent monkeypox (MPOX) outbreak has drawn heightened international concern; however, no effective therapeutic interventions or reliable strategies to prevent its spread are currently available. Here, we developed a nano‐silver (Ag)‐selenium (Se) liquid dressing (lll) by conjugating Ag and Se nanoparticles with a commercial liquid dressing. After administration to the lesion sites, this unique formulation demonstrated highly effective antiviral properties in a surrogate MPOX mouse model (characterised by skin lesions/rashes) induced by vaccinia virus infection. In addition, AgSe@LD showed pronounced anti‐inflammatory activity and accelerated the healing process of virus‐infected cutaneous lesions. Remarkably, AgSe@LD formed a thin film that exhibited excellent adhesion and stability when applied to lesions, while showing resistance to water, alcohol and soapy water washing, thus offering great potential for practical application. This simple and effective liquid dressing represents a major breakthrough in the management of skin infections and provides new ideas for the treatment of MPOX.
- 28 May 2026
- Published by Wiley in Exploration
- Vol. 6 (3)
Open AccessNano‐Silver‐Selenium Liquid Dressing Facilitates Treatment of Monkeypox and Prevention of Viral Transmission in a Surrogate Mouse Model
The recent monkeypox (MPOX) outbreak has drawn heightened international concern; however, no effective therapeutic interventions or reliable strategies to prevent its spread are currently available. Here, we developed a nano‐silver (Ag)‐selenium (Se) liquid dressing (lll) by conjugating Ag and Se nanoparticles with a commercial liquid dressing. After administration to the lesion sites, this unique formulation demonstrated highly effective antiviral properties in a surrogate MPOX mouse model (characterised by skin lesions/rashes) induced by vaccinia virus infection. In addition, AgSe@LD showed pronounced anti‐inflammatory activity and accelerated the healing process of virus‐infected cutaneous lesions. Remarkably, AgSe@LD formed a thin film that exhibited excellent adhesion and stability when applied to lesions, while showing resistance to water, alcohol and soapy water washing, thus offering great potential for practical application. This simple and effective liquid dressing represents a major breakthrough in the management of skin infections and provides new ideas for the treatment of MPOX.
- Open Access
- 27 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (40) , e23716
Microglia‐Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis‐Associated Encephalopathy
Sepsis‐associated encephalopathy (SAE), the most prevalent and severe complication of sepsis, is a leading cause of long‐term cognitive deficits and increased mortality. Although anti‐inflammatory and antioxidant therapies have advanced, single‐target drugs cannot disrupt the complex inflammatory cascade in SAE. Therefore, multi‐target synergistic strategies are urgently needed. This study developed a multifunctional biomimetic nanodrug, ME@FDsi, for precise SAE therapy. The system uses a tetrahedral framework nucleic acid (tFNA) as a carrier, connected via base complementary pairing with small interfering RNA (siTNFα) to target TNF‐α. It is also loaded with disulfiram (DSF) to inhibit pyroptosis. The resulting FDsi was encapsulated in erythrocyte membrane vesicles modified with the M1 microglia‐targeting MG1 peptide. ME@FDsi exhibits a nanovesicle structure, prolonged circulation, stability, and biocompatibility. In SAE mice, it crosses the compromised blood‐brain barrier and targets M1 microglia via MG1, releasing DSF and siTNF‐α intracellularly. DSF blocks pyroptosis and IL‐1β release, while siTNFα silences TNF‐α expression. Additionally, tFNA scavenges reactive oxygen species. Together, these actions shift microglia from the M1 to the M2 phenotype. ME@FDsi treatment improved cognitive function, reduced multi‐organ damage, and increased survival in SAE mice. This multi‐mechanism synergistic approach offers a promising therapeutic strategy for clinical SAE and sepsis.
- 27 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (40) , e23716
Open AccessMicroglia‐Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis‐Associated Encephalopathy
Sepsis‐associated encephalopathy (SAE), the most prevalent and severe complication of sepsis, is a leading cause of long‐term cognitive deficits and increased mortality. Although anti‐inflammatory and antioxidant therapies have advanced, single‐target drugs cannot disrupt the complex inflammatory cascade in SAE. Therefore, multi‐target synergistic strategies are urgently needed. This study developed a multifunctional biomimetic nanodrug, ME@FDsi, for precise SAE therapy. The system uses a tetrahedral framework nucleic acid (tFNA) as a carrier, connected via base complementary pairing with small interfering RNA (siTNFα) to target TNF‐α. It is also loaded with disulfiram (DSF) to inhibit pyroptosis. The resulting FDsi was encapsulated in erythrocyte membrane vesicles modified with the M1 microglia‐targeting MG1 peptide. ME@FDsi exhibits a nanovesicle structure, prolonged circulation, stability, and biocompatibility. In SAE mice, it crosses the compromised blood‐brain barrier and targets M1 microglia via MG1, releasing DSF and siTNF‐α intracellularly. DSF blocks pyroptosis and IL‐1β release, while siTNFα silences TNF‐α expression. Additionally, tFNA scavenges reactive oxygen species. Together, these actions shift microglia from the M1 to the M2 phenotype. ME@FDsi treatment improved cognitive function, reduced multi‐organ damage, and increased survival in SAE mice. This multi‐mechanism synergistic approach offers a promising therapeutic strategy for clinical SAE and sepsis.
- Open Access
- 16 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (18) , e2500430
Dual‐Atom Catalyst Au@S‐rGO for Rapid and Highly Sensitive Electrochemical Detection of Fentanyl in Serum
Fentanyl is a highly lethal emerging drug that requires urgent rapid trace detection. In this work, high‐sensitivity detection of fentanyl is achieved by Au‐ and S‐doped reduced graphene oxide (Au@S‐rGO). Spherical electron microscopy revealed that Au and S existed in an atomically dispersed state. The possible configurations of S in Au@S‐rGO, as well as the effects of different doping positions on the electron density of Au, are analyzed by Density functional theory (DFT) simulations. The co‐modification of metal and nonmetal atoms significantly improves the catalytic activity of the electrode. The optimal electrode delivers a good linear relationship for fentanyl concentrations from 0.0291 to 38.2 µmol L‐1, with a detection limit of 9.7 nmol L‐1. The recovery rate of fentanyl in human serum ranged from 98.0% to 104%, demonstrating the precision of the sensor in real biological matrices. Furthermore, by employing rats in place of drug addicts, the coincidence rate between the electrochemical test results and the mass spectrometry results was 85.7% ~ 93.6%. Compared with mass spectrometry, the sensor offers faster, simpler, and more cost‐effective onsite detection. In summary, the novel diatomic catalyst design looks excellent for fabricating electrochemical sensors for the rapid detection of fentanyl in real samples.
- 16 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (18) , e2500430
Open AccessDual‐Atom Catalyst Au@S‐rGO for Rapid and Highly Sensitive Electrochemical Detection of Fentanyl in Serum
Fentanyl is a highly lethal emerging drug that requires urgent rapid trace detection. In this work, high‐sensitivity detection of fentanyl is achieved by Au‐ and S‐doped reduced graphene oxide (Au@S‐rGO). Spherical electron microscopy revealed that Au and S existed in an atomically dispersed state. The possible configurations of S in Au@S‐rGO, as well as the effects of different doping positions on the electron density of Au, are analyzed by Density functional theory (DFT) simulations. The co‐modification of metal and nonmetal atoms significantly improves the catalytic activity of the electrode. The optimal electrode delivers a good linear relationship for fentanyl concentrations from 0.0291 to 38.2 µmol L‐1, with a detection limit of 9.7 nmol L‐1. The recovery rate of fentanyl in human serum ranged from 98.0% to 104%, demonstrating the precision of the sensor in real biological matrices. Furthermore, by employing rats in place of drug addicts, the coincidence rate between the electrochemical test results and the mass spectrometry results was 85.7% ~ 93.6%. Compared with mass spectrometry, the sensor offers faster, simpler, and more cost‐effective onsite detection. In summary, the novel diatomic catalyst design looks excellent for fabricating electrochemical sensors for the rapid detection of fentanyl in real samples.